- Acalabrutinib2021 | Third Faculty of Medicine
- Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results2022 | Faculty of Medicine in Hradec Králové
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia2020 | Central Library of Charles University
- Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C32020 | Faculty of Pharmacy in Hradec Králové
- Fixed duration therapy in patients with chronic lymphocytic leukemia2023 | Publication without faculty affiliation
- Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?2021 | Faculty of Medicine in Hradec Králové
- Managing BTK inhibitor treatment-related adverse events in patients with chronic lymphocytic leukaemia - cardiovascular complications and bleeding2023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Bruton's tyrosine kinase inhibitors and their current status in the treatment of chronic lymphocytic leukemia2023 | First Faculty of Medicine
- Modern approach to the treatment of chronic lymphocytic leukemia2023 | Faculty of Medicine in Hradec Králové
- On the road to optimized BTK inhibition in CLL2021 | Publication without faculty affiliation